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Abstract
Background: The impact of immunosuppression despite virological suppression (immuno-virological discordance, ID) on
the risk of developing fatal and non-fatal AIDS/non-AIDS events is unclear and remains to be elucidated.
Methods: Patients in EuroSIDA starting at least 1 new antiretroviral drug with CD4,350 cells/ml and viral load (VL).500
copies/mL were followed-up from the first day of VL,= 50 copies/ml until a new fatal/non-fatal non-AIDS/AIDS event.
Considered non-AIDS events included non-AIDS malignancies, pancreatitis, severe liver disease with hepatic
encephalopathy (.grade 3), cardio- and cerebrovascular events, and end-stage renal disease. Patients were classified
over time according to whether current CD4 count was above (non-ID) or below (ID) baseline level. Relative rates (RR) of
events were calculated for ID vs. non-ID using adjusted Poisson regression models.
Results: 2,913 patients contributed 11,491 person-years for the analysis of non-AIDS. 241 pre-specified non-AIDS events
(including 84 deaths) and 89 AIDS events (including 10 deaths) occurred. The RR of developing pre-specified non-AIDS
events for ID vs. non-ID was 1.96 (95% CI 1.37–2.81, p,0.001) in unadjusted analysis and 1.43 (0.94–2.17, p = 0.095) after
controlling for current CD4 count. ID was not associated with the risk of AIDS events (aRR 0.76, 95% CI 0.41–1.38, p = 0.361).
Conclusion: Compared to CD4 responders, patients with immuno-virological discordance may be at increased risk of
developing non-AIDS events. Further studies are warranted to establish whether in patients with ID, strategies to directly
modify CD4 count response may be needed besides the use of ART.
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Introduction
Combination antiretroviral therapy (cART) mainly exerts its
effect on the reduction of HIV related morbidity and mortality by
suppressing HIV viral load which leads to an increase of CD4 cells
[1,2]. A rapid increase of CD4 cells is important in the light of the
fact that a significant proportion of patients continue to present for
therapy when advanced immunodeficiency is present and their
immediate risk of AIDS and death is high [3]. The majority of
patients achieve a sustained reconstitution of CD4 cells upon
starting cART [4] although blunted CD4 responses do also occur
in patients initiating when their CD4 count was ,200 cells/ml
[5,6,7]. The inability to achieve an increase in CD4 count in the
context of sustained virological suppression is also known as
immuno-virological discordance (ID) [8] and has been associated
with increased mortality [9]. Indeed, previous work from the
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ClinSurv Study group showed an association between ID and the
risk of AIDS and death [10]. However, this risk was greatly
reduced with longer time spent with a suppressed viral load
suggesting that maintaining a suppressed viral load is key for
patients with immuno-virological discordance [10]. Previous data
indicate that non-AIDS events are nowadays important contrib-
utors to HIV associated morbidity and mortality and that current
CD4 is also a predictor of these events [11]. The role of immuno-
virological discordance to predict the risk of fatal and non-fatal
non-AIDS and AIDS events remains unclear and was evaluated in
this analysis. The aim of our analysis was to investigate whether a
lack of any increase in CD4 count above levels observed prior to
starting a suppressive regimen and despite evidence of sustained
viral suppression was associated with adverse clinical progression.
Methods
EuroSIDA Cohort
The EuroSIDA study is a prospective, observational cohort
study including HIV-1 infected patients from 31 European
countries as well as Israel and Argentina [12].
To date, nine cohorts have been enrolled starting in May 1994.
At enrollment, demographic characteristics and clinical informa-
tion are obtained. Every 6 months CD4 count and viral load data
as well as data on antiretroviral drugs used are collected in a
standardized report form and forwarded to the coordinating
center. The pre-specified non-AIDS events included are those
used in previous EuroSIDA publications on this topic [11] and the
expert opinion of members of the steering committee as events
which are likely to have a major impact of HIV associated
morbidity and mortality. These data have been routinely collected
since January 2001 and include non-AIDS malignancies, pancre-
atitis, severe liver disease with hepatic encephalopathy (grade 3 or
4), cardio- and cerebrovascular events (i.e. myocardial infarction,
placement of coronary artery bypass graft or angioplasty, carotid
endarterectomy, stroke), and end-stage renal disease. Death from
all causes except for AIDS related conditions was counted as non-
AIDS defining. Diagnoses of AIDS are recorded using the clinical
1993 CDC definition [13] and causes of deaths are categorized
using the Coding Cause of Death in HIV (CoDe) classification
[14]. Members of the coordinating office visit all centers at least
once a year to ensure correct patient selection and to verify that
data are accurate. In patients with a clinical event, all entered data
are checked against case files and 10% of case files are checked in
all other patients.
Ethics Statement
Each of the centers participating in EuroSIDA sought ethical
clearance according to local regulations and laws and patients gave
their informed consent to take part in the study. All data were
anonymized prior to statistical analysis. The senior investigator at
each clinical site is responsible for obtaining and maintaining this/
these approval(s) at all times during the conduct of the study. Full
study details are available at www.cphiv.dk.
Patient Selection
Patients in the cohort with a CD4 count of less than 350 cells/ml
who after 1 January 2001 started at least one new antiretroviral
drug with most recent viral load .500 copies/mL (either because
starting their first cART or because switching drugs after failing on
their previous regimen) and subsequently achieved viral suppres-
sion ,= 50 copies/mL were included. Follow-up accrued from
the first day of viral suppression below 50 copies/mL following the
initiation of the new regimen (baseline) until the first of either a
fatal or non-fatal non-AIDS or AIDS event, viral rebound .50
copies/mL (defined as the time of the first of 2 consecutive values
above this threshold) or patients’ latest available follow-up visit in
which they were known to be still event-free. Each AIDS and non-
AIDS condition which developed during follow-up was counted as
one event and recurrences of the same condition were not
counted.
Data were left-censored at entry in the cohort and patients had
to have at least one month of prospective follow-up after baseline
to be included. CD4 counts were carried forward until a new CD4
test was performed.
Statistical Methods
Immuno-virological response was defined using both the CD4
count measured prior to initiation of the suppressive regimen and
the current CD4 count. In particular if patients’ current CD4
count was still equal or below the pre-ART initiation level then the
person was defined as immuno-virological discordant (ID) at the
time of the current CD4 count measure. In contrast, any current
rise in CD4 count above pre-ART level would reverse his/her
classification to immunological responder (non-ID). Rates of fatal
and non-fatal non-AIDS and AIDS events were calculated over 6
monthly periods (0–6, 7–12, 13–18, 19–24, .24 months) of
virological suppression after baseline and stratified according to ID
status. Univariable and multivariable Poisson regression models
were performed to estimate the risk associated with a current ID
status (fitted as a time-dependent covariate). When exploring the
magnitude of the risk associated with being ID over time, a
categorical covariate grouping periods of follow-up with thresholds
0–6, 7–12, 13–18, 19–24, .24 months and using the 0–6 months
period as the comparator group was included in the model. Other
potential risk factors or confounders which were considered for
inclusion in the model were: age, hepatitis C serostatus, mode of
HIV transmission, race, cohort of origin, the number of previous
ART regimens used, current CD4 count (or baseline CD4 count in
an alternative model) and specific antiretroviral drugs included in
the newly initiated regimen.
Potential confounders were selected on the basis of prior
knowledge and when hypothesized to be common causes of both
the exposure of interest and the risk of developing the outcome. A
software based on directed acyclic graphs [15] was employed to
identify the appropriate model to correctly estimate the direct
effect of ID condition on the risk of the outcomes.
To be consistent with previous analysis of the data of the cohort,
current CD4 count was fitted on a log2 scale as this was shown to
improve the goodness of fit of the model. Models also included
time from initiation of new regimen to viral suppression, current or
previous smoking, history of impaired renal function at baseline
(defined as an estimated Cockroft-Gault glomerular filtration rate
,60 mg/dL/1.73 m2), anaemia (defined as haemoglobin levels
,14 mg/dl in males and,12 mg/dl in females), diabetes (defined
as having previously started any antidiabetic treatment or
diagnosis of insulin dependent diabetes), and hypertension (defined
as a systolic/diastolic blood pressure.= 140/.= 90 mmHg
mmHg or previous initiation of any antihypertensive treatment).
Separate analyses were performed for two endpoints (fatal and
non-fatal non-AIDS, and fatal and non-fatal AIDS) using a
competing risk approach (i.e. by truncating follow-up at July 01,
2011 instead of the date at which a competing event occurred). In
brief, the competing event (e.g. a non-AIDS event in the case of a
cause specific analysis with an AIDS event as endpoint) was
removed to avoid overestimation of the cumulative probability of
AIDS events [16]. The cause of death was used to define the non-
AIDS (only deaths from any cause that were unrelated to AIDS
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are included) and AIDS (only deaths from AIDS related causes are
included) endpoints. We assumed that deaths due to other reasons
(e.g. suicide) did not have an indirect effect on the probability to
develop AIDS or other non-AIDS co-morbidities and therefore
patients’ follow-up was censored at the date of death for these
reasons. Of note, because we adopted combined endpoint such as
‘AIDS events’ the issue of competing risk of developing, say, a PCP
prior to a diagnosis of, say, Kaposi sarcoma is automatically
removed. For the non-AIDS endpoint we performed sensitivity
analyses in the subsets of patients who were treatment-naı¨ve when
they started the new baseline regimen and of those who achieved
complete viral suppression within a maximum of 1 year after
starting the new baseline regimen. The latter analysis aimed at
reducing potential bias introduced by participants who may have
experienced adherence or tolerability issues on the newly started
regimen. In a further sensitivity analysis we modified the main
inclusion criterion by including patients who started the new
regimen with a CD4 count ,200 cells/ml (instead of 350) and
consequently used this lower cut-off for the definition of time-
dependent immuno-virological discordance.
The likelihood ratio test was used to test temporal trends and,
more in general, to compare the difference in goodness of fit of
nested models (for example models with or without specific
interaction terms). STATA v12.1 was used for all analyses. All p-
values were two sided and a value of ,0.05 was considered
significant unless it was a subgroup analysis for which we required
the p-value to be smaller than 0.05/k where k was the total
number of identified groups (Bonferroni correction).
Results
A total of 2,913 patients satisfied the inclusion criteria for this
analysis (Figure 1). Median age was 42 (range 20–82) years.
Seventy two percent of patients were male and the most common
transmission risk was men having sex with men (38%). At time of
initiation of the new regimen the majority of patients (55%) had a
CD4 count of 200–350 cells/ml and 25% had never previously
received antiretroviral treatment. One third of patients (33%) had
experienced clinical AIDS prior to starting the new regimen.
These and other characteristics of patients at initiation of the new
regimen (baseline) are shown in Table 1.
Fatal and Non-fatal Non-AIDS
For the primary endpoint, fatal and non-fatal non-AIDS,
11,491 person years of follow-up were available and 241 events
including 157 non-AIDS disease events and 84 non-AIDS deaths
occurred. Malignancies classified as not AIDS related were the
most common disease events (n = 72, 46%) followed by cerebro-
vascular diseases (n = 46, 39%). Kaplan Meier estimate of median
survival time in patients who died was 2.1 (95% CI 1.6–2.8) years.
Malignancies (n = 23, 27%) were also the most common causes of
death. 42 (17%) fatal or non-fatal non-AIDS events occurred in ID
patients (rate 53/1,000PYFU [95% CI 38–72]) vs. 199 (83%) in
patients without ID (rate 19/1,000PYFU [95% CI 16–21])
p,0.001 (Figure 2).
In the adjusted Poisson regression analysis including demo-
graphic and clinical parameters (Table 2; model 1) the risk of fatal
and non-fatal non-AIDS was almost two-fold higher in patients
currently classified as ID compared to those classified as non-ID
(aRR 1.96, 95% CI 1.37–2.81, p,0.001) Point estimates were
slightly lower in a model adjusted for demographic factors as well
as baseline CD4 count (Table2; model 2). After adjusting for
current CD4, only a tendency for an association between ID and
the risk of non-AIDS remained (aRR 1.43, 95% CI 0.94–
2.17,p = 0.095).
Compared to the first 6 months of viral suppression (reference
group), the adjusted relative rate of experiencing fatal or non-fatal
non-AIDS for patients classified as ID was 1.06 (95% CI 0.32–
3.50) in month 7–12, 0.81 (95% CI 0.23–2.81) in month 13–18,
1.67 (95% CI 0.51–5.41) in month 19–24 and 0.91 (95% CI 0.23–
3.60) thereafter, test for trend p = 1.00). Similarly, there was no
tendency for a decline in risk in periods in which patients were
classified as non-ID (month 7–12: aRR 0.97, 95% CI 0.55–1.72,
month 13–18 aRR 1.25, 95% CI 0.71–2.18, month 19–24 aRR
0.59, 95% CI 0.28–1.23, and .24 months aRR 1.14, 95% CI
0.63–2.07, p-value for test of trend = 0.24).
Factors besides ID and current CD4 count significantly
associated with the risk of developing the composite endpoint in
the main analysis included older age, a diagnosis of anaemia prior
to baseline, previous non-AIDS, and current use of antiretroviral
treatment consisting of less than 3 drugs (Table 3).
Sensitivity Analyses for the Non-AIDS Endpoint
The association between ID and the risk of non-AIDS events
appeared to be higher in patients who were therapy-naı¨ve
(aRR = 3.06, 95% CI 0.69–13.55) vs. those who were treatment
experienced (aRR = 1.30, 95% CI 0.84–2.02) at baseline, although
there was no evidence of interaction (p-value = 0.583).
After restricting our analysis to patients who achieved viral
suppression within one year after initiation of cART (n = 1,489,
51% of total follow-up for 6,333 person years and 162 events), the
association between ID and the risk of developing non-AIDS
events (aRR 1.63, 95% CI 0.95–2.78, p = 0.073) was consistent
with that found in the main analysis. In a sub-analysis of ART
naı¨ve patients who achieved complete virological suppression
within one year (21 events only), ID was marginally significantly
associated with non-AIDS even after controlling for current CD4
(aRR for ID 4.54, 95% CI 0.97–21.2, p = 0.054).
Results were similar in a sensitivity analysis defining virological
failure as one viral load .50 regardless of confirmation (data not
shown).
In the analysis using the alternative cut-off of 200 CD4 cells/ml
(n = 1,349, 170 events, 5247 PYFU), results were also similar: aRR
2.39, 95% CI 1.37–4.18, p = 0.002) in the model adjusted only for
demographic and clinical factors and aRR 1.58, 95% CI 0.81–
3.12, p = 0.183) after further controlling for current CD4 count.
Fatal and Non-fatal AIDS
In the separate analysis with AIDS as an endpoint, 11,723
person years of follow-up were available. A total of 89 AIDS events
including 10 AIDS-related deaths occurred. Oesophageal candi-
diasis was a frequently observed opportunistic infection (n = 15,
17%) followed by pulmonary and extrapulmonary tuberculosis (14
patients, 16%). Kaplan Meier estimate of median survival time in
patients who died was 1.3 (95% CI 0.3–2.0) years. AIDS
malignancies were the most common cause (n = 8, 80%).
ID was significantly associated with the risk of developing
AIDS-related events when adjusted for demographic and clinical
factors only (aRR 1.86, 95% CI 1.07–3.23, p = 0.03). However,
after adjusting for current CD4 count, ID was no longer
independently associated (aRR 0.76, 95% CI 0.41–1.38,
p = 0.36). Factors significantly associated with the risk of develop-
ing AIDS included current CD4 (aRR 0.50 per doubling of the
count, 95% CI 0.40–0.62, p,0.001), diagnosis of anaemia at
baseline (aRR 2.21, 95% CI 1.46–3.35, p,0.001), and a previous
AIDS condition (different from that observed in follow-up, aRR
2.07, 95% CI 1.33–3.20, p = 0.001).
Immuno-Virological Discordance and Non-AIDS/AIDS
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Discussion
In our analysis, we found that people who failed to achieve a
CD4 count above the level present at the time of starting a new
regimen, despite having achieved and maintained viral suppres-
sion ,50 copies/mL on ART, tended to have an increased risk of
developing non-AIDS morbidity and mortality. Because of the
wide confidence interval around our estimate, our results may be
considered inconclusive. However, a two-fold increased risk in
people with ID cannot be excluded. Our results should guide
further investigations using larger study populations to test
whether the lack of statistical significance was due to limited
power of our analysis. Of note, the association was independent of
demographic characteristics and baseline CD4 count but seemed
to be mainly explained by a low current CD4 count. There was a
small residual independent effect but only in people who started
the new regimen when they were ART-naı¨ve and who achieve
virological suppression within one year. In additions, there was no
evidence for a decreasing risk of non-AIDS events with longer time
with a viral load ,= 50 copies/mL in people with or without ID.
Our data suggest that in order to reduce the risk of non-AIDS
events in people starting therapy with a CD4,350 cells/ml,
continuous monitoring for difference between current CD4 count
and the level registered at the time of initiation of a new regimen
may be considered starting as early as the first 6 months following
viral suppression. The cut-off of 350 CD4 cells/ml as baseline was
chosen as this represents the threshold below which cART is
generally recommended. However, also when the alternative cut-
off of 200 CD4 cells/ml was used, our results were similar although
the analyses had reduced statistical power.
In a previous analysis, ID was associated with a higher risk of
AIDS and death [10]. However, this analysis was unadjusted for
current CD4 count and only included patients initiating their first
cART from ART-naı¨ve at ,200 CD4 cells/ml in a cohort in
Germany. Because of the different inclusion criteria as well
different definitions of ID patients, results cannot be directly
compared.
Previous analyses of EuroSIDA data demonstrated that current
CD4 count is a significant predictor of the risk of non-AIDS events
although the association was less strong than that found for AIDS
events [11,17]. More specifically, it was previously shown, that
those with a current CD4 count of ,200 cells/ml and with
suppressed viraemia on cART have lower rates of AIDS and, to a
Figure 1. Flow chart showing selection of patients enrolled in EuroSIDA for the analysis.
doi:10.1371/journal.pone.0087160.g001
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Table 1. Patient characteristics.
CD4 count 0–99 cells/ml CD4 count 100–199 cells/ml CD4 count 200–350 cells/ml
No. % No. % No. %
Gender:
Male 415 14.2 562 19.3 1,128 38.7
Female 119 4.1 218 7.5 471 16.2
Ethnicity:
Caucasian 462 15.9 661 22.7 1,382 47.4
Asian 13 0.4 10 0.3 33 1.1
Afro-american 42 1.4 57 2 104 3.6
Unknown 17 0.6 52 1.8 80 2.7
Transmission risk:
MSM 168 5.8 285 9.8 663 22.8
IDU 127 4.4 204 7 349 12
Heterosexual 197 6.8 231 7.9 474 16.3
Unknown 42 1.4 60 2.1 113 3.9
Antiretroviral therapy naı¨ve*:
No 378 13 563 19.3 1,233.0 42.3
Yes 156 5.4 217 7.4 366 12.6
Currently smoking{:
No 190 6.5 252 8.7 577 19.8
Yes 197 6.8 274 9.4 586 20.1
Unknown 147 5 254 8.7 436 15
Hepatitis B coinfection{:
No 434 14.9 649 22.3 1,334.0 45.8
Yes 38 1.3 57 2 123 4.2
Unknown 62 2.1 74 2.5 142 4.9
Hepatitis C coinfection{:
No 326 11.2 462 15.9 1,028.0 35.3
Yes 129 4.4 212 7.3 377 12.9
Unknown 79 2.7 106 3.6 194 6.7
Diabetes mellitus`:
No 470 16.1 690 23.7 1,433.0 49.2
Yes 17 0.6 28 1 54 1.9
Unknown 47 1.6 62 2.1 112 3.8
Arterial hypertension1:
No 319 11 493 16.9 978 33.6
Yes 121 4.2 152 5.2 388 13.3
Unknown 94 3.2 135 4.6 233 8
Anaemia":
No 262 9 455 15.6 1,006.0 34.5
Yes 210 7.2 257 8.8 448 15.4
Unknown 62 2.1 68 2.3 145 5
Impaired kidney function (GFR,60)**:
No 518 17.8 761 26.1 1,573.0 54
Yes 16 0.5 19 0.7 26 0.9
Previous AIDS event{:
No 231 7.9 521 17.9 1,189.0 40.8
Yes 303 10.4 259 8.9 410 14.1
Previous non-AIDS event{:
Immuno-Virological Discordance and Non-AIDS/AIDS
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lesser extent, non-AIDS events compared to patients with ongoing
viral replication [18]. The potential independent role of ID had
not been investigated in this analysis.
In the present study we included time-updated current CD4
count and immuno-virological discordance status, because we
hypothesized that the risk associated with the incapacity to
reconstitute CD4 cells over time may not be fully captured by
Table 1. Cont.
CD4 count 0–99 cells/ml CD4 count 100–199 cells/ml CD4 count 200–350 cells/ml
No. % No. % No. %
No 510 17.5 749 25.7 1,527.0 52.4
Yes 24 0.8 31 1.1 72 2.5
On combination ART*:
No 126 4.3 183 6.3 392 13.5
Yes 408 14 597 20.5 1,207.0 41.4
Median Range Median Range Median Range
Age (years)* 43 23–76 43 20–80 42 20–82
CD4 count at start of new regimen (cells/ml) 47.5 1–99 153 100–199 270 200–350
CD4 count at day of suppression (cells/ml) 206.5 6–1,056 270 35–1,064 380 30–1,492
CD4 nadir (cells/ml) 34 1–99 120.5 1–199 202 1–350
Viral load (log cop/ml){ 5.1 2.7–7.8 4.7 2.7–6.9 4.4 2.7–8.1
Year of first viral suppression ,50 cop/ml{ 2006 2001–2011 2006 2001–2011 2006 2001–2011
Number of previous antiretroviral drugs* 3 0–17 4 0–16 4 0–18
*at start of new regimen.
{at day of first viral suppression (baseline).
`diagnosis of insulin dependent diabetes at baseline or having previously started any antidiabetic treatment.
1systolic/diastolic blood pressure.= 140/.= 90 mmHg mmHg at baseline or previous initiation of any antihypertensive treatment.
"haemoglobin ,14 mg/dl in males and ,12 mg/dl in females at baseline.
**estimated Cockroft-Gault glomerular filtration rate ,60 mg/dL/1.73 m2 at baseline.
doi:10.1371/journal.pone.0087160.t001
Figure 2. Rates (and 95% confidence intervals) of fatal and non-fatal non-AIDS and AIDS in patients with and without immuno-
virological discordance (ID).
doi:10.1371/journal.pone.0087160.g002
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current CD4 count without taking into account the status of
immunosuppression observed prior to starting the suppressive
regimen. A similar approach was also used in a recent study by
Lapadula et al who, however, used a different definition of non-
AIDS events but a similar definition of ID patients and found a
strong association between lack of CD4 count recovery on
suppressive ART and risk of developing the composite endpoint
of AIDS and non-AIDS events [19].
The finding for non-AIDS events is intriguing as it suggests that
patients’ current status of immunodeficiency is not able to fully
explain why some people remain at higher risk of clinical
complications. However, this needs to be confirmed in further
analyses as measurement variability in CD4 tests and differences in
frequencies of measurement may be alternative explanations.
Indeed, it is possible that ID is a marker of one of more
unmeasured factors that put these people at increased risk of an
adverse clinical outcome. For example, immuno-virological
discordance may be the effect of incomplete bone marrow or
thymus output as well as excessive destruction or disturbed
immunoregulation. [20] In addition, lymph node fibrosis could
contribute to persistent low CD4 counts. [21] Furthermore, higher
mortality rates were recently observed in parents of immunological
non-responders suggesting that genetic factors may be involved as
well [22]. In patients with low CD4 counts but suppressed
viraemia higher rates of cellular immune activation markers
including CD38 and HLA-DR together with higher cell-associated
HIV-RNA have been observed and this has been linked
particularly to non-AIDS morbidity and mortality [23]. The
higher immune activation may set the stage for non-AIDS events
including cardiovascular disease [24]. Furthermore, non-AIDS
malignancies have been strongly linked with HIV induced
immunodeficiency [25,26]. In our analysis, we failed to show an
effect of ID which was independent of current CD4 count. This
can be due to lack of power or characteristics of the study
population included. Indeed, when restricting to fully adherent
persons who started a new regimen from ART-naı¨ve we obtained
stronger evidence for an independent effect. Of note, in contrast,
there was no significant association between ID status and the risk
of AIDS events.
Our study has some limitations: first, the non-AIDS conditions
considered here as endpoint-defining events represent a subset of
non-AIDS events causing HIV morbidity. However, this selection
has been previously used [11]. Second, based on our restrictive
inclusion criteria, the numbers of people with an event is quite low
and we were not able to investigate the risk associated with specific
groups of conditions separately (for example we could hypothesize
that the risk associated with being ID varies by specific
malignancy). In addition, it was not possible to obtain robust
estimates of the event rates after 24 months from baseline in the ID
group due to the low number of patients remaining at risk after
this time point.
In conclusion, patients with immuno-virological discordance, in
the context of suppressed viral load appeared to be at higher risk of
fatal and non-fatal non-AIDS events although most of this
increased risk seems to be explained by a low current CD4 count.
An independent effect was found only in the subset of ART-naı¨ve
patients who experienced a rapid virological response. Another
important finding was that this increased risk, if it exists, does not
seem to decrease with longer duration of viral suppression,
suggesting that such patients should remain under close follow-up
for change in CD4 count from pre-therapy level, also after
extended periods of being on cART. If this observation is
confirmed in other studies it has profound implications as it
suggests that cART alone may not be able to substantially remove
the risk of non-AIDS in patients identified as ID. To date,
strategies to directly influence immune reconstitution by adding
interleukin-2 or by modifying cART regimens have failed to show
benefit over viral suppression alone [27,28]; therefore new
strategies perhaps aiming at other mechanisms to boost functional
CD4 cells or decreasing the levels of immune-activation (e.g.
interleukin-7, probiotics) need to be tested in people who show
incomplete immune reconstitution despite sustained viral suppres-
sion.
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